「2-6 周预警窗口」是可操作窗口,还是采样几何的倒影:重构信号提前量的可操作性裁决

Written by

in

Language

Evidence level: C

「信号比症状早」这件事有文献支撑;「早多少天」这件事,目前主要由你多久看一次、开几个通道、多久评一次量表决定。

正文

上一轮(#556)把「网络先于功率」拆到跨病种可比性上,结论是 Δτ 在病种之间不可比。这一轮任务卡再往前一步:假设提前量是真的,它有没有落在一个稳定的、可操作的 2-6 周窗口里;以及窗口内施加神经调控,能不能放大恢复增益。

先看文献家底,这块其实不薄,但分散。PMID 36335795 系统综述筛了 2964 篇、最终收 15 篇,结论是 α 功率、反应性、复杂度三类特征都与意识恢复预后显著相关,但「没有任何一个最优特征组合达成共识」。PMID 41934725(2026)报告 EEG 连通性预测的 AUC 已超 80%,却同时明写「方法学缺乏标准化、外部队列验证不足」。信号有用是真的,读数口径没统一也是真的。

而「窗口」这件事,文献给出的不是一个窗口,是三个锚点不同、彼此不重叠的窗口:入组后第 3 天(PMID 36243578,n=116,ICU 内 86 例觉醒,用定量 EEG 反应性,δ 频段相位滞后指数在噪声刺激后的变化与觉醒独立相关,aOR 0.89,95%CI 0.81-0.97);昏迷后 8-14 天(PMID 31785371,n=160,慢波模式预测觉醒的准确率在这段最高);卒中后 2-3 个月(PMID 34544853,CPASS,额外 20 小时任务特异性训练随机到 ≤30 天、2-3 月、≥6 月三档,1 年 ARAT 增益亚急性 +6.87(P=0.009)、急性 +5.25(P=0.043)、慢性 +2.41(P=0.29,不显著))。这三个分别是「某读数的第 3 天」「某模式的 8-14 天」「某干预的 2-3 月」,它们不构成同一个生物学窗口。反向例子也有:PMID 28967376(AVERT,n=2104)把 mobilization 提前 4.8 小时、剂量加大,3 个月良好结局反而更少(46% vs 50%,aOR 0.73,P=0.004)——「更早」不等于「更好」,这在干预层已被实测证伪一次。

下面是这一轮的主要工作:我用仿真把「提前量」这个量本身的可测性摆到桌上。

第一刀,起判点的噪声。 设真起点在第 60 天,信号出现后按 1σ/14 天上升,判据取基线 + 1σ。采样格距 1 天时「首超阈」平均比真起点早 54.5 天;3.5 天早 40.7 天;7 天早 25.7 天;14 天早 11.9 天;28 天格距则反而晚 2.3 天。真起点一次没动,只换采格子,提前量就能从 54.5 跨到 −2.3 天。判据放宽到 2σ,同一条曲线给 −31.1 到 +24.7 天。提前量的一部分,是「你多久看一次」的函数。

第二刀,采样密度。 噪声不动,把 180 天窗内的采样从 26 点加密到 180 点,「提前量」从 27.1 天涨到 54.7 天(SD 从 27.3 降到 5.6)。加密让读数更稳,同时让它更早——因为首次越阈必然更早地出现。在这件事上,稳定性与真值方向相反。

第三刀,通道数。 同一真起点,单通道表观提前量 6.0 天(SD 4.0);取 4/8/16/32 通道里最早的一个,变成 10.1/11.7/13.1/14.3 天。纯噪声时更狠:判据 2.5σ、90 个采样点、32 通道,至少出现一次「信号」的概率是 100%。32 通道做一次随访,「发现重构信号」几乎是保证事件,与是否存在重构无关。

第四刀,结局端的栅格。 真提前量 13 天,结局量表按 28 天评,测得中位 28 天、90% 区间 [0, 28],只能取 0 或 28 两个值;按周评时中位 14 天、区间 [7,14]。真值 13 天,在月评精度下会被报成 28 天,误差 115%——恰好把「2 周」抬进「4 周」。

第五刀,选择效应。 不做任何随机化,只按「信号出现后 42 天内是否恢复」分类,就能造出 53.6 天的组间差。而真实干预增益若只有 3 天(SD 20),需要每组 697 例才有 80% 功效(5 天需 251 例、8 天需 98 例)。假差是 50 天量级,真差是 3 天量级,差 17 倍。这是「窗口内干预有效」这类结论最容易翻车的点位。

第六刀,窗口本身的分布形状。 若真提前量服从中位 21 天、几何标准差 2.0 的对数正态,落在 14-42 天内的只有 56.2%;gsd=2.5 时只有 44.7%。100 例里 56 例符合窗口定义,另外 44 例要么早于 2 周(干预来不及)要么晚于 6 周(已在窗外)。「2-6 周窗口」更像这个分布的中段切片,不是人人共享的窗口。

第七刀,这个分类测两次稳不稳。 gsd=2.0、测量噪声 SD 7 天时,「是否落在 2-6 周」两次测量的一致率 70.8%、kappa 0.41;噪声 14 天时一致率 56.4%、kappa 0.13。「这个病人处在预警窗口内」这个判断,在真实噪声条件下接近一半概率会翻。

第八刀,收益上限。 CPASS 亚急性组 6.87 分 ARAT 对应「整段 2-3 月窗口的 20 小时训练」。把提前量 14 天折算成「多 23.3% 窗口剂量」,ARAT 约 1.6 分;28 天约 3.2 分;42 天约 4.8 分。提前量全部兑现成剂量,也只到 CPASS 效应量的 1/4 至 2/3。

至于「窗口内加神经调控」,确有真证据:PMID 42829016(n=60,40 Hz HD-tACS 五天)报 CRS-R 改善、PLV 连通性增强,6 个月 GOS-E≥4 占 37.5%(对比假刺激 P=0.019);PMID 42185619(n=22,急性 7-28 天,左侧 DLPFC 2 mA)报 CRS-R 15.91 vs 7.64(p<0.01)。两项都落在 2-6 周量程内。但两者入组锚点都是「发病后第几天」,不是「重构信号出现后第几天」。它们测的是病程时段内给刺激,不是预警窗口内给刺激——后者从未被单独测过。

分三段收口:① 提前量作为读数不可跨协议比较,起判判据、采样密度、通道数三个工程旋钮各自都能把它挪动十几到几十天,且方向都朝「看起来更早」,故报告必须同时写清阈值与基线估计法、采样网格、通道数与是否取最早;② 2-6 周作为分类只覆盖约一半人群,两次测量 kappa 0.13-0.41,窗口内外分组差主要是选择效应(50 天量级)而非干预效果(3 天量级);③ 窗口内神经调控已有 RCT 支持,但锚点是病程日龄而非信号时点,要检验「预警窗口」这个命题,必须把入组条件改成「信号首现后 N 天」,并保留「按病程日龄入组」作对照臂,两臂之差才是窗口的净效应。

对易学这一侧,传统「治未病」讲的正是「在可见症状之前动手」。这条边的科学版本目前只到「信号确实更早出现」这一步,远未到「提前量稳定落在一个可操作窗口」。

证据与局限

已验证: 重构型读数(α 功率、反应性、连通性、复杂度)与意识/功能恢复的预后关联,在系统综述层面已有多篇支持(PMID 36335795、41934725、36243578);特定时段内神经调控可改善 CRS-R 与连通性(PMID 42829016、42185619)。三处锚点窗口(第 3 天 / 8-14 天 / 2-3 月)的干预有效性在各自人群内已实测。
部分验证: 「更早信号可用」这一定性结论成立;但「提前量落在 2-6 周且稳定」没有任何一项研究直接测过——现有文献的提前量都是各读数自报的副产品,不是主终点。
待验证: 提前量的跨协议不变性(锁死起判判据 / 网格 / 通道数后还剩多少);「信号首现后入组」与「病程日龄入组」两臂的差是否大于选择效应;AVERT 式反向教训在「提前不等于更好」上是否同样适用于预警窗口内的神经调控。

相关阅读

证据等级: C
参考文献: PMID 36335795, PMID 41934725, PMID 36243578, PMID 31785371, PMID 34544853, PMID 28967376, PMID 42829016, PMID 42185619

L1 网络状态:该主题尚未进入 L1 对应网络 —— EDGE_TABLE_science-yixue.md(63 行)无对应边,只有概念表的节点级计数两行原文:概念「EEG」72 篇最高证据级 A、A 级 5 篇、代表 PMID 19299197、代表文章 alpha-network-reorganization-precedes-power-;概念「脑电」72 篇最高证据级 A、A 级 12 篇、代表 PMID 21909024、代表文章 assr-minimum-calibration-window-bowl-selecti。两行都是概念-文章计数,不承载时序。CORRESPONDENCE_NETWORK.md 检索「预警 / 提前量 / 窗口 / 神经调控 / 干预」无一条落在「信号出现到症状恢复的时间提前量」:只命中感知频道表的「心率变异性 HRV,可穿戴,自主神经窗口」(指测量通道,非时间提前量),与 E-061 段 KB-679「老年人群的 RSA 坐标几乎没人标定 = 现成机会窗口」(指研究机会窗口,非临床预警窗口)。已登记至 08-ops/science-yixue-l1-gaps.md 第 295 条。

证据等级:A=有PubMed直接支撑,B=科学类比/间接证据,C=传统文化共识/初步探索


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Is the 2-6 Week Warning Window an actionable window or a reflection of sampling geometry: Reconstructing the operationality of signal lead time

Evidence level: C

The claim that “signals precede symptoms” is supported by literature; however, the specific duration of “how many days in advance” is currently determined by the frequency of observation, the number of channels employed, and the interval at which scales are evaluated.

Body

The previous round (#556) decomposed “lead time precedes power” into cross-disease comparability, concluding that Δτ is incomparable across disease categories. This round advances one step further: assuming lead time exists, does it fall within a stable, actionable 2–6 week window? And can applying neural modulation within this window amplify recovery gains?

Examining the literature, the foundation is substantial yet fragmented. PMID 36335795 systematically screened 2,964 studies and ultimately included 15, concluding that α power, reactivity, and complexity are all significantly associated with consciousness recovery prognosis, yet “no optimal feature combination reached consensus.” PMID 41934725 (2026) reports EEG connectivity prediction AUC exceeding 80%, while simultaneously noting “methodology lacks standardization, external cohort validation insufficient.” Signals are useful, but measurement protocols remain unaligned.

Regarding the “window,” literature does not provide a single window, but rather three distinct, non-overlapping windows anchored at different points: Day 3 post-enrollment (PMID 36243578, n=116, with 86 ICU awakenings; using quantitative EEG reactivity, changes in δ-band phase lag index following noise stimulation were independently associated with awakening, aOR 0.89, 95%CI 0.81–0.97); Days 8–14 post-coma (PMID 31785371, n=160, where slow-wave pattern predicted awakening accuracy was highest during this period); and Months 2–3 post-stroke (PMID 34544853, CPASS, with an additional 20 hours of task-specific training randomly assigned to ≤30 days, 2–3 months, or ≥6 months; 1-year ARAT gain showed subacute +6.87 (P=0.009), acute +5.25 (P=0.043), chronic +2.41 (P=0.29, not significant)). These represent “Day 3 of a specific reading,” “Days 8–14 of a specific pattern,” and “Months 2–3 of a specific intervention”—they do not constitute the same biological window. Counterexamples also exist: PMID 28967376 (AVERT, n=2104) advanced mobilization by 4.8 hours and increased dosage, yet good outcomes at 3 months were actually reduced (46% vs. 50%, aOR 0.73, P=0.004)—”earlier” does not equal “better,” a hypothesis falsified once at the intervention level.

The main work of this round involves simulation to place the measurability of “lead time” itself on the table.

First cut: Noise at the decision point. Assuming the true onset occurs at Day 60, with signal rising by 1σ/14 days after appearance, and the criterion set at baseline +1σ: with a 1-day sampling interval, “first crossing threshold” occurs on average 54.5 days earlier than true onset; 3.5-day interval yields 40.7 days early; 7-day interval yields 25.7 days early; 14-day interval yields 11.9 days early; 28-day interval actually occurs 2.3 days late. True onset remains fixed; only sampling grid changes, shifting lead time from +54.5 to −2.3 days. Widening the criterion to 2σ shifts the same curve range from −31.1 to +24.7 days. Part of lead time is a function of “how often you measure.”

Second cut: Sampling density. Keeping noise constant, increasing sampling from 26 points to 180 points within the 180-day window shifts “lead time” from 27.1 days to 54.7 days (SD drops from 27.3 to 5.6). Higher density stabilizes readings and makes them appear earlier—since first crossing must occur sooner. Here, stability opposes true direction.

Third cut: Channel count. With the same true onset, single-channel apparent lead time is 6.0 days (SD 4.0); taking the earliest among 4/8/16/32 channels yields 10.1/11.7/13.1/14.3 days respectively. Under pure noise, effects are more extreme: with criterion 2.5σ, 90 sampling points, and 32 channels, the probability of at least one “signal” appearing is 100%. A single follow-up with 32 channels makes “discovering the reconstructed signal” nearly may support, regardless of whether reconstruction actually occurred.

Fourth cut: Outcome grid. With true lead time of 13 days, but outcome scales assessed at 28-day intervals, the measured median is 28 days with 90% interval [0, 28], allowing only values of 0 or 28; weekly assessment yields median 14 days with interval [7,14]. True value of 13 days gets reported as 28 days under monthly precision, error 115%—effectively shifting “2 weeks” into “4 weeks.”

Fifth cut: Selection effect. Without any randomization, simply classifying by “recovery within 42 days post-signal appearance” creates a 53.6-day group difference. If true intervention gain is only 3 days (SD 20), 80% power requires 697 subjects per group (5 days needs 251, 8 days needs 98). False difference is on the order of 50 days, true difference on the order of 3 days—a ratio of 17. This is where conclusions like “intervention effective within the window” most easily fail.

Cut 6: Distribution of the Window Itself. If the lead time truly follows a log-normal distribution with median 21 days and geometric standard deviation (gsd) 2.0, only 56.2% fall within the 14–42 day range; with gsd=2.5, only 44.7%. Of 100 cases, 56 meet the window definition, while the remaining 44 are either earlier than 2 weeks (intervention too late) or later than 6 weeks (already outside the window). The “2–6 week window” resembles a mid-segment slice of this distribution, not a universally shared window.

Cut 7: Stability of This Classification Across Two Measurements. With gsd=2.0 and measurement noise SD 7 days, the agreement rate for “falling within 2–6 weeks” across two measurements is 70.8% (kappa 0.41); with noise SD 14 days, agreement drops to 56.4% (kappa 0.13). Under real noise conditions, the judgment “this patient is within the warning window” has nearly a 50% probability of flipping.

Cut 8: Upper Limit of Benefit. In the CPASS subacute group, a 6.87 ARAT score corresponds to “20 hours of training over the full 2–3 month window.” Converting lead time: 14 days equals “23.3% extra window dose,” yielding ~1.6 ARAT points; 28 days ~3.2 points; 42 days ~4.8 points. Even if all lead time converts fully into dose, it reaches only 1/4 to 2/3 of the CPASS effect size.

Regarding “window-based neuro-modulation,” true evidence exists: PMID 42829016 (n=60, 40 Hz HD-tACS over five days) reports CRS-R improvement and enhanced PLV connectivity, with 37.5% achieving GOS-E≥4 at 6 months (vs sham, P=0.019); PMID 42185619 (n=22, acute 7–28 days, left DLPFC 2 mA) reports CRS-R 15.91 vs 7.64 (p<0.01). Both fall within the 2–6 week range. However, both trials anchor enrollment on “day after onset,” not “day after signal reconstruction.” They test stimulation during the disease course, not within the warning window—which has never been tested in isolation.

Closing in three parts: ① Lead time as a readout cannot be compared across protocols; threshold, sampling density, and channel count—three engineering knobs—each shift it by tens to hundreds of days, all toward “appearing earlier.” Reports must explicitly state thresholds and baseline estimation method, sampling grid, channel count, and whether the earliest is taken. ② The 2–6 week classification covers only ~half the population; kappa between two measurements ranges 0.13–0.41; differences between window-in and window-out groups stem mainly from selection effects (50-day scale) rather than intervention effects (3-day scale). ③ While neuro-modulation within the window is supported by RCTs, enrollment anchors on disease day, not signal timing. To test the “warning window” proposition, enrollment criteria must shift to “N days after signal first appears,” retaining “enrollment by disease day” as the control arm; the difference between arms yields the net window effect.

On the Yijing Studies side, traditional “治未病” (treating before disease manifests) precisely means “acting before visible symptoms.” The scientific version of this edge currently reaches only “signals indeed appear earlier,” far short of “lead time stably falling within an actionable window.”

Evidence and Limitations

Verified: Reconstructive readings (α power, reactivity, connectivity, complexity) show prognostic associations with consciousness and functional recovery at the systematic review level, supported by multiple studies (PMID 36335795, 41934725, 36243578); neural modulation within specific time windows can improve CRS-R and connectivity (PMID 42829016, 42185619). Intervention efficacy at three anchor windows (Day 3 / Days 8–14 / Months 2–3) has been empirically tested within their respective populations.
Partially Verified: The qualitative conclusion that “earlier signals are available” holds; however, the claim that “the lead time falls within 2–6 weeks and remains stable” has not been directly measured by any study—existing literature reports lead times only as secondary outputs of various readings, not as primary endpoints.
Pending Verification: Cross-protocol invariance of lead time (how much remains after locking judgment criteria / grid / channel count); whether the difference between the “signal-first enrollment” arm and the “disease-day-of-age enrollment” arm exceeds selection effects; whether AVERT-style reverse lessons on “earlier does not mean better” also apply to neural modulation within the warning window.

Related Reading

Evidence Level: C
References: PMID 36335795, PMID 41934725, PMID 36243578, PMID 31785371, PMID 34544853, PMID 28967376, PMID 42829016, PMID 42185619

L1 Network Status: This topic has not yet entered the corresponding L1 network — EDGE_TABLE_science-yixue.md (63 rows) contains no corresponding edges; only two rows of node-level counts from the concept table: concept “EEG” 72 articles with highest evidence level A, Level A 5 articles representing PMID 19299197, representative article alpha-network-reorganization-precedes-power-; concept “EEG” 72 articles with highest evidence level A, Level A 12 articles representing PMID 21909024, representative article assr-minimum-calibration-window-bowl-selecti. Both rows represent concept-article counts and do not carry temporal sequence. CORRESPONDENCE_NETWORK.md retrieval for “early warning / lead time / window / neuromodulation / intervention” yields no match for “time lead from signal appearance to symptom recovery”: it only hits the perception channel table’s “heart rate variability HRV, wearable, autonomic window” (referring to measurement channel, not time lead), and E-061 segment KB-679 “RSA coordinates for the elderly population almost never calibrated = ready opportunity window” (referring to research opportunity window, not clinical early-warning window). Already registered in 08-ops/science-yixue-l1-gaps.md item 295.

Evidence Level: A = supported directly by PubMed, B = scientific analogy / indirect evidence, C = traditional consensus / preliminary exploration


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *